



Joint Working Executive Summary

The Cancer Vanguard Interactive Medicines Optimisation and Compliance Dashboard and Evaluation Framework

In response to the 'Pharma Challenge', the Cancer Vanguard worked in partnership with Celgene to deliver a proof of concept project to develop an 'Interactive Medicines Optimisation and Compliance Dashboard and Evaluation Framework'. The Cancer Vanguard is made up of The Christie, Manchester, The Royal Marsden NHS Foundation Trust, London and University College London Hospitals NHS Foundation Trust.

The Interactive Medicines Optimisation and Compliance Dashboard uses the Systemic Anti-Cancer Therapy (SACT) dataset. It enables a visual analysis of the underlying SACT data and identifies potential sub-optimal use of medicines. It also facilitates the multi-disciplinary team to review and amend prescribing with respect to utilisation of treatment, where appropriate, to improve patient outcomes.

The Evaluation Framework appraises the service delivery models used across the Cancer Vanguard (a) from the patient perspective and (b) in terms of the operational and financial impacts for the NHS. The objective being to offer better choice and experience for patients, encouraging treatment compliance/optimisation, whilst understanding the impact on NHS resources, ideally identifying cost saving or cost neutral options.

The project ran from February 2017 to December 2018. Throughout the course of the work all stakeholders engaged positively, resulting in the delivery of an interactive Medicines Optimisation Dashboard and Evaluation Framework, in line with the agreement.

NP-UK-NA-0367

Date of Preparation: April 2019